Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
🤖 D.R.A.F.T. Summary
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical […]
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →